Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Laek Therapeutics Shanghai Co Ltd
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NISC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Discontinued Products
RAC Alpha Serine/Threonine Protein Kise (Protein kise B or Protein kise B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registratiol MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jun 17, 2019: ArQule announces prelimiry results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Feb 06, 2019: Rexahn announces presentation on its drug candidate RX-0201 at the 2019 ASCO Genitouriry Cancers Symposium
Nov 16, 2018: ArQule presents clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
Nov 12, 2018: NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly
Nov 08, 2018: ArQule to present clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI symposium
Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)
Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting
Sep 13, 2018: Miransertib (ARQ 092) granted fast track desigtion for the treatment of PIK3CA-related overgrowth spectrum (PROS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Rexahn Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019